Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
RAD adds brain tumor technology to portfolio 2022-06-10 10:21
BIORCHESTRA, presenting lead candidate BMD-001 for Alzheimer's disease and drug delivery system technology at the 2022 BIO International Convention 2022-06-09 20:30
Brii Biosciences Announces Positive Data from a Randomized, Single-Blind Study of its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China 2022-06-09 19:00
Standigm Signs MOU with Merck Korea for AI drug Discovery Research 2022-06-09 14:46
Sciwind Biosciences to present Data from its GLP-1 and GIP Receptor Agonist Programs at The International Liver Congress(TM) EASL 2022 2022-06-09 08:00
Amaroq Therapeutics hits early milestones and makes key appointments to Scientific Advisory Board 2022-06-09 00:05
Medison Pharma Announces the Approvals by Health Canada and Therapeutics Goods Administration of KIMMTRAK® (tebentafusp) for the Treatment of Unresectable or Metastatic Uveal Melanoma 2022-06-08 23:54
OnCusp Therapeutics and Multitude Therapeutics Enter into an Ex-China Licensing Agreement for a Potentially Highly Differentiated CDH6-Targeting Antibody Drug Conjugate 2022-06-08 20:00
FDA Advisory Committee Recommends Emergency Use Authorization of Novavax COVID-19 Vaccine for People Aged 18 Years and Older 2022-06-08 09:23
ASCO 2022 | Ascentage Pharma Releases for the First Time Results of its FAK/ALK/ROS1 inhibitor APG-2449 Demonstrating Safety and Efficacy in Patients with Advanced NSCLC 2022-06-08 08:00
ASCO 2022 | Ascentage Pharma Releases Updated Data Demonstrating Lisaftoclax's (APG-2575) Therapeutic Potential in Patients with R/R CLL/SLL 2022-06-08 08:00
First Patient Enrolled in SELUTION SLR IDE BTK Study 2022-06-08 08:00
Innovent Announces Phase 2 study of Mazdutide（IBI362） in Chinese Participants with Overweight or Obesity Met Primary and All Key Secondary Endpoints 2022-06-08 08:00
Chordia Therapeutics Announces Interim Results of the Phase 1 Clinical Trial of CLK Inhibitor CTX-712 at the 2022 ASCO Annual Meeting 2022-06-07 14:00
Chordia Therapeutics Announces Interim Results of the Phase 1 Clinical Trial of CLK Inhibitor CTX-712 at the 2022 ASCO Annual Meeting 2022-06-07 14:00
Antengene Announces HREC Approval in Australia for the Phase I Trial of the Small Molecule ATR Inhibitor ATG-018 2022-06-07 11:34
ASCO 2022 | Ascentage Pharma Releases Updated Results Demonstrating the Therapeutic Potential of Alrizomadlin (APG-115) plus Pembrolizumab in Patients with Solid Tumors who Progressed on Immunotherapies 2022-06-07 11:30
ASCO 2022 | The First Dataset of Olverembatinib (HQP1351) in Patients with GIST Demonstrates Therapeutic Potential with a Clinical Benefit Rate of 83.3% 2022-06-07 11:28
Pharmactive Enters Strategic Partnership with Nutraconnect for APAC 2022-06-07 09:00
iNtRON Completes GLP-TOX Studies of BAL200 2022-06-07 09:00
1 130 131 132 133 134 375